Marshall Fordyce Sells 17,500 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Marshall Fordyce sold 17,500 shares of the firm’s stock in a transaction dated Wednesday, January 8th. The stock was sold at an average price of $41.74, for a total transaction of $730,450.00. Following the completion of the transaction, the chief executive officer now directly owns 143,603 shares in the company, valued at $5,993,989.22. This represents a 10.86 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Marshall Fordyce also recently made the following trade(s):

• On Wednesday, December 18th, Marshall Fordyce sold 17,500 shares of Vera Therapeutics stock. The stock was sold at an average price of $43.07, for a total transaction of $753,725.00.
• On Wednesday, December 11th, Marshall Fordyce sold 17,500 shares of Vera Therapeutics stock. The shares were sold at an average price of $46.94, for a total value of $821,450.00.
• On Wednesday, October 23rd, Marshall Fordyce sold 19,375 shares of Vera Therapeutics stock. The stock was sold at an average price of $40.39, for a total value of $782,556.25.

Vera Therapeutics Price Performance

Shares of VERA opened at $37.02 on Friday. The company has a 50 day moving average of $45.41 and a two-hundred day moving average of $41.01. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17. Vera Therapeutics, Inc. has a twelve month low of $14.20 and a twelve month high of $51.61. The company has a market cap of $2.34 billion, a price-to-earnings ratio of -14.18 and a beta of 1.15.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.21). As a group, analysts predict that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Vera Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Vera Therapeutics by 21.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,983 shares of the company’s stock valued at $86,000 after acquiring an additional 350 shares in the last quarter. Public Employees Retirement Association of Colorado purchased a new stake in Vera Therapeutics during the 2nd quarter worth approximately $135,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Vera Therapeutics during the 2nd quarter valued at approximately $163,000. Quarry LP purchased a new position in shares of Vera Therapeutics in the second quarter worth $235,000. Finally, HighVista Strategies LLC acquired a new stake in shares of Vera Therapeutics during the second quarter worth $331,000. Institutional investors and hedge funds own 99.21% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. Wedbush increased their price target on Vera Therapeutics from $30.00 to $38.00 and gave the stock a “neutral” rating in a research report on Friday, November 8th. JPMorgan Chase & Co. raised their target price on shares of Vera Therapeutics from $72.00 to $75.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $107.00 price target on shares of Vera Therapeutics in a research report on Tuesday, October 1st. Wells Fargo & Company initiated coverage on shares of Vera Therapeutics in a research note on Thursday, November 21st. They issued an “overweight” rating and a $70.00 price objective for the company. Finally, Scotiabank began coverage on Vera Therapeutics in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $60.00 target price on the stock. One analyst has rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $63.50.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.